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The class II lysyl-tRNA synthetases (KRS) are conserved aminoacyl-tRNA synthetases that attach
lysine to the cognate tRNA in a two-step mechanism. The enzyme from the parasitic protozoan Ent-
amoeba histolytica was crystallized in the presence of small ligands to generate snapshots of the
lysine-adenylate formation. The residues involved in lysine activation are highly conserved and
the active site closes around the lysyl-adenylate, as observed in bacterial KRS. The Entamoeba
EMAPII-like polypeptide is not resolved in the crystals, but another Entamoeba-speciﬁc insertion
could be modeled as a small helix bundle that may contribute to tRNA binding through interaction
with the tRNA hinge.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The aminoacyl-tRNA synthetases (aaRS) are enzymes that spe-
ciﬁcally attach an amino acid to the 30-end of its corresponding
tRNA in a two steps reaction. In the ﬁrst step, the enzyme binds
ATP and the amino acid, and catalyzes the formation of an amino-
acyl-adenylate intermediate. In the second step, the amino acid
moiety is transferred to the terminal adenosine of the cognate
tRNA molecule. The aaRS are divided in two classes that evolved
from unrelated common ancestors corresponding to the catalytic
core of today aaRS [1–3]. During the course of evolution many aaRS
have gained additional domains and functions, particularly themammalian enzymes [4]. The combination of a conserved catalytic
core and idiosyncratic features of individual aaRS make them
attractive potential targets for the development of new drugs for
infectious diseases.
In class II aaRS, KRS belongs to the subclass IIb, together with
aspartyl- and asparaginyl-tRNA synthetases (DRS and NRS), which
share a conserved topology of the N-terminal anticodon-binding
domain, described as the oligonucleotide-binding (OB) fold [5]. In
addition to its canonical activity, KRS gained additional domains
and functions through evolution, especially in higher eukaryotes.
Homo sapiens KRS (HsKRS) is thus involved in the regulation of
transcription [6], cell migration [7], HIV infection [8] and death sig-
naling [9]. It is associated with the Charcot–Marie–Tooth (CMT)
disease [10] and the amyotrophic lateral sclerosis (ALS) [11] (see
[12] for a detailed review). HsKRS is part of a multi-aaRS complex
composed of nine aaRS and three accessory proteins [4]. This com-
plex is thought to be a reservoir of regulation molecules beyond
their aminoacylation function.
Entamoeba histolytica is an amitochondriate unicellular proto-
zoan and the major cause of dysentery in the world, with an esti-
mation of 50 million people infected and more than 100,000
deaths annually [13]. If the parasite manages to cross the epithelial
Table 1
Data statistics for the EhKRS structures.
PDBID 4UP7 4UP8 4UP9 4UPA
Ligand Lys-AMP – ATP AMPPNP
Crystallization
Reservoir solution 50 mM HEPES pH 8.0, 50 mM NaCl, 1 mM
Spermine, 8% PEG 4000
100 mM HEPES pH 7.5, 10% PEG
6000, 5% MPD
50 mM HEPES pH 8.0, 50 mM NaCl, 7.5% PEG 4000,
1.2 mM Spermine
50 mM HEPES pH 8.0, 50 mM NaCl, 7.5% PEG 4000,
1.2 mM Spermine
Volume 1 ll + 1 ll 1 ll + 1 ll 1 ll + 1 ll 1 ll + 1 ll
Temperature (C) 20 20 20 20
Cryoprotectant 20% MPD 20% MPD 20% MPD 20% MPD
Data collection
Wavelength (Å) 1.000 1.000 1.000 1.000
Space group P 62 P 62 P 62 P 62
Unit-cell parameters a, b, c
(Å)
155.6, 155.6, 95.2 156.5, 156.5, 93.5 155.5, 155.5, 92.9 156.8, 156.8, 94.1
a, b, c () 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 120
Resolution range (Å)a 37.4–2.8 (2.95–2.8) 34.5–2.9 (3.07–2.9) 43.9–3.05 (3.26–3.05) 39.2–2.9 (3.1–2.9)
Total no. of reﬂections 746,923 (103,260) 181,472 (24,814) 151,673 (25,766) 178,742 (23,738)
No. of unique reﬂections 32,784 (4,645) 29,106 (4,645) 24,433 (4,274) 29,250 (4,659)
Completeness (%) 99.5 (96.9) 99.8 (99.4) 99.1 (96.3) 99.7 (99.0)
Average redundancy 22.8 (22.2) 6.2 (5.3) 6.2 (6.0) 6.1 (5.1)
hI/r(I)i 22.8 (1.8) 12.2 (0.9) 8.8 (1.1) 15.2 (1.1)
Rmeas
d 0.126 (2.287) 0.144 (2.123) 0.195 (1.624) 0.108 (1.703)
CC1/2b 0.999 (0.645) 0.997 (0.324) 0.994 (0.490) 0.998 (0.462)
Overall B factor from
Wilson plot (Å2)
77 83 79 84
Reﬁnement
Resolution range (Å) 36.0–2.8 (2.9–2.8) 34.5–2.9 (3.0–2.9) 40.4–3.05 (3.16–3.05) 38.7–2.9 (3.0–2.9)
Completeness (%) 99.6 (95.7) 99.8 99.1 99.7
No. of reﬂections, working
set
32761 (3152) 29098 (2849) 24402 (2296) 29226 (2863)
Final Rcryst 0.205 (0.374) 0.216 (0.378) 0.216 (0.336) 0.203 (0.382)
Final Rfree 0.225 (0.451) 0.251 (0.409) 0.263 (0.391) 0.236 (0.381)
No. of non-H atoms
(Protein/Ligand) 4239/32 4449/- 4020/31 4099/31
Protein residues 529 580 514 515
rmsdc
From ideal bond lengths
(Å)
0.006 0.007 0.007 0.008
From ideal bond angles () 1.045 1.220 1.108 1.166
Average B factors (Å2)
(Protein/Ligand) 86/79 83/- 86/120 80/120
Ramachandran plot
Most favoured (%) 93.3 92.9 92.5 94.7
Outliers (%) 0.2 1.2 0.8 0.6
Molprobity validation
Rotamer outliers (%) 0.2 0.9 0.5 0.9
Cb outliers 0 0 0 0
Clashscore 5.39 6.94 6.25 5.69
a Values for the outer shell are given in parentheses.
b According to [49]. The highest resolution using the criteria CC(1/2) > 0.5 and mean I/r(I) > 2 is 2.88 Å.
c Using ideal values from [50].
d Rmeas is the redundancy-independent merging R factor [51].
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Table 2
Rmsd values among KRS structures.
PDB:chain 4UP8:A 4UP9:A 4UPA:A 4UP7:A 3BJU:B 4PG3:C 4H02:E
Species E. his E. his E. his E. his H. sap P. fal P. fal
Ligands – ATP AMPPNP Lys-AMP ATP, Lys Clad, Lys –
4UP8 0.4 0.5 1.7 2.3 2.0 1.6
4UP9 0.3 1.4 2.1 1.8 1.5
4UPA 1.4 2 1.8 1.5
4UP7 1.4 1.3 1.7
3BJU 1.4 1.9
4PG3 1.4
Abbreviations are: E. his, Entamoeba histolytica; H. sap, Homo sapiens; P. fal, Plasmodium falciparum; Clad, Cladosporin.
4480 L. Bonnefond et al. / FEBS Letters 588 (2014) 4478–4486gut barrier, it can reach internal organs and cause systemic infec-
tions and internal lesions such as amebic liver abscesses [14].
The side effects of the available drugs and the emergence of
drug-resistance call for the development of new drugs. In the
genus Entamoeba, lysyl- and methionyl-tRNA synthetases (EhKRS
and EhMRS) share a common C-terminal domain of 166 amino
acids. This domain is highly similar to the human endothelial
monocyte activating polypeptide II (EMAPII), and was named Ent-
amoeba EMAPII-like polypeptide (EELP) [15]. Human EMAPII is an
inﬂammatory cytokine that induces apoptosis and migration in
endothelial cells [16]. In Entamoeba, EELP is proteolytically
released from the EhKRS and localized at the surface of the para-
site. This polypeptide was proposed to facilitate the escape of Ent-
amoeba from the host immune system, through modulation of the
host cellular environment [15].
Class II KRS crystal structures have been solved in bacteria and
eukaryotes: namely Escherichia coli [17–19], Thermus thermophilus
[20], Geobacillus stearothermophilus [21], Burkholderia thailandensis
[22], Plasmodium falciparum [23,24] and Homo sapiens [25,26]. The
bacterial structures, solved in the presence of different small
ligands, helped deciphering the catalytic mechanism and revealed
conformational changes upon lysine binding [19]. The crystal
structure of HsKRS revealed the existence of a tetrameric form of
the enzyme. Finally, KRS structures from Burkholderia and Plasmo-
dium were solved in an effort to develop new potential drug tar-
gets. Here we solved crystal structures of E. histolytica KRS in its
apo form and in complex with small ligands. The structures reveal
conformational changes in the catalytic domain upon lysine bind-
ing, as seen in the bacterial KRS structures. In all structures the
EELP is not visible, but another Entamoeba-speciﬁc insertion within
the catalytic domain could be built. This 60 amino acid-long inser-
tion, folded in a compact helix bundle, might mediate additional
interactions with the cognate tRNA molecule.
2. Materials and methods
2.1. Protein expression and puriﬁcation
E. coli C41(DE3) cells were transformed with pET30-EhKRS vec-
tor [15]. The resulting recombinant protein harbors an amino-ter-
minal hexahistidine tag and two additional residues from the
cloning process (MHHHHHHML instead of the initial M). The
DNA sequencing of the pET30-EhKRS also revealed a point muta-
tion V764I at the C-terminus of the EhKRS sequence (Entry
C4M7X2). The protein expression was induced for 4 h at 37 C,
with 1 mM Isopropyl b-D-1-thiogalactopyranoside in LB medium.
The cells were harvested by centrifugation and resuspended in
10 ml per pellet g of buffer A [100 mM Tris–HCl, pH 7.5, 300 mM
NaCl, 10 mM MgCl2, 14 mM 2-Mercaptoethanol (2-ME), and
20 mM imidazole] supplemented with 1 mM Phenylmethylsul-
fonyl ﬂuoride. After sonication, the lysate was centrifuged at
40,000  g for 30 min at 4 C. The supernatant was mixed with
2 ml of NiNTA superﬂow resin (Qiagen) per liter of culture,incubated for 1 h at 4 C, and then loaded on an Econo column
(Bio-Rad). After washing the column with 10 column volumes
(c.v.) of buffer A, the bound protein was eluted with 5 c.v. of buffer
A supplemented with 500 mM imidazole. The sample was mixed
with two volumes of buffer A without NaCl to decrease the NaCl
concentration to 100 mM. The diluted sample was loaded on a
10 ml HiTrap Heparin HP column (GE Healthcare) equilibrated in
buffer B [50 mM Tris–HCl pH 7.5, 100 mM NaCl, 10 mM MgCl2,
14 mM 2-ME and 5% glycerol] and developed with a linear gradient
of 0.1–1.0 M NaCl. The fractions containing the protein were
pooled and loaded on a Hiload 16/60 Superdex 200 prep grade col-
umn (GE Healthcare) equilibrated in buffer C [10 mM Tris–HCl pH
7.5, 100 mM NaCl, 10 mM MgCl2 and 2 mM Dithiothreitol]
(Fig. S1). The fractions containing the protein were pooled and con-
centrated to 20 mg ml1 on an Amicon Ultra-15 10kDa MWCO
(Millipore). The yield of recombinant protein was 15 mg per liter
of LB medium culture. Samples were either directly used for crys-
tallization or ﬂash-frozen as 25 ll aliquots in liquid nitrogen and
stored at 80 C.
2.2. Crystallization
Crystallization conditions were screened using 6 commercially
available kits [PACT and JCSG+ (Qiagen), ACTA/JB3 (in-house, Jena
Bioscience), Index I/II and CS I/II (Hampton Research), and Wizard
I/II (Emerald BioStructures)] by the sitting-drop vapor-diffusion
method. The protein was used at 20 mg ml1 in the absence or
presence of 5 mM ATP. Drops of 100 nl protein solution + 100 nl
mother liquor were made with a Mosquito robot (TTP Labtech)
and stored at 20 C. Initial hits were obtained for 65 conditions
with a mother liquor composed of a buffer at pH 7.0–9.0, a salt
at 50–200 mM and 25% PEG 1500 to 10% PEG 8000 as a precipitant.
These conditions were reﬁned using the hanging drop diffusion
method with 2 ll drops (1 ll protein + 1 ll mother liquor) in 24-
well VDXm™ plates (Hampton Research) using 22 mm siliconized
glass cover slides (Hampton Research). Large crystals
(0.5  0.3  0.3 mm3) were obtained within 3 days in the presence
of 5 mM ATP from drops with crystallization solution containing
either 50 mM HEPES-NaOH, pH 8.0, 50 mM NaCl 7.5% PEG 4000,
1.2 mM spermine. Co-crystallizations were performed in the same
conditions with adenosine triphosphate (ATP), phosphoamino-
phosphonic acid-adenylate ester (AMPPNP), and lysine at 5 mM
ﬁnal concentration each (Table 1).
2.3. Data collection and structure determination
Crystals were soaked in the crystallization solution supple-
mented with 20% 2-methyl-2,4-pentanediol (MPD) and ﬂash-fro-
zen in liquid nitrogen. Datasets were collected either at the
SPring8 BL41XU beamline, using a Rayonix MX225HE CCD detector
or at the Photon Factory NE3A beamline, using an ADSC Q270 CCD
detector, and processed with XDS [27]. Datasets were merged with
Aimless [28,29]. The crystals belong to the P62 space group with
Fig. 1. Structure based alignment of KRS sequences. Structures are from EhKRS apo-form, HsKRS (PDBID 3BJU, [25]) and PfKRS (PDBID 4H02, [23]). The alignment was done
with PDBeFold [34] and formatted with Espript [52]. Conserved residues are highlighted in red, equivalent residues are written in red and framed. Black stars indicate
residues that interact with ATP, lysine and Lys-AMP. The secondary structure elements of EhKRS are indicated above the alignment. Colours used are: orange for the
anticodon-binding domain, green for the catalytic domain, purple for the Entamoeba-speciﬁc insertion and black for the linker. The EhKRS EELP at the C-terminal end is
omitted.
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solved by molecular replacement using HsKRS structure (PDBID
3BJU, [25]) as the search model. Iterative cycles of model building
and reﬁnement were carried out using Coot [30], PHENIX [31] and
PDB_REDO [32]. Data statistics tables were prepared from Aimless
logs, with the phenix.table_one utility and Molprobity analysis [33]
(Table 1).
2.4. Structural analysis
Root mean square deviations (rmsd) among KRS structures
(Table 2) were calculated over equivalent Ca positions using the
Protein structure comparison service Fold (PDBeFold) at European
Bioinformatics Institute (http://www.ebi.ac.uk/msd-srv/ssm/),
which is based on the SSM algorithm [34]. Disorder prediction
was performed with the meta Protein DisOrder prediction System
(metaPrDOS, http://prdos.hgc.jp) [35]. The models of tRNA bound
EhKRS and EhDRS were built using the yeast DRS-tRNAAsp complexstructure (PDBID 1ASY, [36]) as a reference. To position the yeast
tRNAAsp over the Entamoeba aaRS, the aaRS structures were super-
imposed on their catalytic domains using the SSM algorithm. The
EhDRS insertion was built from the available structure factors
(PDBID 3I7F, [37]). Structural ﬁgures were drawn with CueMol
(http://cuemol.sourceforge.jp/en/).
3. Results and discussion
3.1. Overall structure
Four EhKRS structures have been determined at the 2.8–3.1 Å
resolution range, in its apo form and in the presence of different
small ligands. The enzyme is 769 amino acids long, and can be
decomposed in a N-terminal anticodon-binding domain (residues
1–137), a catalytic domain (residues 150–554), a linker (residues
563–580) and the C-terminal EELP (residues 603–769) (Fig. 1). In
all structures, residues 304–368 between strands b13 and b14,
Fig. 2. Entamoeba histolytica KRS structure. (A) EhKRS apo-form dimer drawn as a
cartoon model. A transparent surface model is added for one of the monomers,
while the cartoon of the other monomer is outlined in black. The colour code is that
from with Fig. 1 with loops coloured in white. Several secondary elements are
labelled for clarity. (B) Close-up on the Entamoeba-speciﬁc insertion domain. A
simulated annealing mFo – DFc composite omit map was drawn around the domain
and contoured at 0.28 e/Å3 (1.0 r).
4482 L. Bonnefond et al. / FEBS Letters 588 (2014) 4478–4486residues 507–513 between helices a15 and a16, and residues after
position 583 are disordered. Residues 304–368 could be built in
the apo-form structure, and residues 507–513 in the lysyl-adenyl-Fig. 3. Comparison of KRS structures. (A) Superposition of EhKRS apo structure (PDBID 4
EhKRS Lys-AMP-bound structure (PDBID 4UP7) on H. sapiens KRS (PDBID 3BJU, [25]) in
canonical amino- and carboxyl-terminal extremities of the KRS.ate (Lys-AMP) bound structure. The asymmetric unit contains one
EhKRS monomer, and the active dimer is formed with the symmet-
ric monomer in the 2-fold axis (Fig. 2). The enzyme is a dimer in
solution, with an apparent molecular weight of 180kDa measured
by size exclusion chromatography (Fig. S1). Unlike the HsKRS [25],
no tetramer was observed for EhKRS either in solution or in the
crystals. The overall structure of EhKRS is very similar to that of
HsKRS and PfKRS structures with rmsd values are in the 1.0–
2.0 Å range (Table 2). EhKRS complex with AMPPNP has a rmsd
of 1.5 Å over 453 Ca positions with PfKRS apo form (Fig. 3A), while
EhKRS complex with Lys-AMP has a rmsd of 1.4 Å over 490 Ca
positions with HsKRS in complex with lysine and an ATP analog
(Fig. 3B). As compared to HsKRS and PfKRS, EhKRS helix a1 in
the anticodon-binding domain is shifted by up to 3 Å to accommo-
date the linker, and the strands b13 and b14 are also shifted by 2–
3 Å to accommodate the Entamoeba-speciﬁc insertion domain. The
presence of this insertion however does not modify the relative
conformation of the catalytic and anticodon-binding domains.
The conformation of the loop between helices a13 and a14, lining
the upper border of the catalytic site, adopts a different conforma-
tion in EhKRS due to present of a single proline residue (P413),
instead of the 2 and 3 prolines in PfKRS and HsKRS, respectively.
EhKRS does not present an internal disulphide bond between heli-
ces a15 and a16, as observed for PfKRS, but salt bridges between
R495 in a15 and E517 in a16 may play an analogous role.
3.2. Absence of the Entamoeba EMAPII-like polypeptide in the electron
density map
Although the full length EhKRS was crystallized, the EELP is not
visible in any crystal structure. The solvent content in the EhKRS
crystals is of 67.6%, which is a high value [38,39]. This fact is likely
correlated to the diffraction limit of the crystals that could not be
improved below 2.8 Å. In the crystal form obtained, the packing
interactions are limited and always involve the hexahistidine tag
(Fig. S2). The protein was also puriﬁed without its tag in an attempt
to obtain a different crystal form, but this construction did not
yield any crystal (see Supplementary information). The analysis
of the EhKRS molecule positions in the unit cell reveals theUP8) on P. falciparum KRS structure (PDBID 4H02, [23]) in red. (B) Superposition of
blue. The Lys-AMP molecule is drawn as a stick model. N and C labels indicate the
Fig. 4. Substrate binding in the EhKRS structures. Stick models of the bound
AMPPNP (A), ATP (B) and Lys-AMP (C) molecules and the EhKRS interacting
residues. Residues interacting through their main chain are drawn as thinner stick
models. Residues are labelled. Equivalent residues of HsKRS are drawn as semi-
transparent stick models on panel (C) and coloured in blue. Simulated annealing
mFo – DFc omit maps were computed by removing the ligand molecules and were
drawn and contoured at 0.13 e/Å3 (1.2r) (A), 0.14 e/Å3 (1.3 r) (B), and 0.11 e/Å3
(1.1 r) (C).
Fig. 5. Conformational changes in KRS structures upon lysine binding. (A) Confor-
mational changes between AMPPNP- and Lys-AMP-bound EhKRS structures in
yellow and blue, respectively. (B) Conformational changes between free (PDBID
1BBW) and lysine-bound (PDBID 1BBU) E. coli LysS structures in yellow and blue,
respectively [19]. Proteins are drawn as Ca traces and the ligands as stick models.
Several secondary elements are labelled for clarity. Secondary elements labels for E.
coli LysS are from [19].
L. Bonnefond et al. / FEBS Letters 588 (2014) 4478–4486 4483presence of large solvent channels and voids that could accommo-
date the missing EELP (Fig. S3). The solvent content of the EhKRS
crystals if EELP was missing would be 74.9%, which is unlikely. In
addition, the homologous EMAP-II from p43 [40] and EMAP-II-like
domain from the human tyrosyl-tRNA synthetase [41] fold in a
compact structure. Finally, a disorder prediction of EELP suggests
only the very last residues as disordered (Fig. S4). It is therefore
likely that this domain is present and folded in the crystal but
adopt different orientations, resulting in a diffuse scattering signal.
A similar phenomenon has previously been postulated for other
aaRS appended domains [42]. Such ﬂexibility between the EhKRS
catalytic core and EELP is in agreement with its role as a standalone
cytokine [15].
3.3. Structural basis of lysyl-adenylate formation
EhKRS has been crystallized in the presence of ATP, the non-
hydrolysable ATP analogue AMPPNP, and lysine. The substrates
of the amino acid activation reaction are held in a deep hydropho-
bic cleft by a network of hydrogen bonds. The cleft is surrounded
by the antiparallel b-sheet and loops from the catalytic domain
(Fig. 3B). The bound ATP and AMPPNP molecules adopt a bent con-
formation with the b- and c-phosphates folded toward the adenine
ring, as in all class II aaRS (Fig. 4). Both structures are very similar,
conﬁrming that AMPPNP is a good unreacted ATP analogue. The N1
and N6 nitrogen of the adenine base make hydrogen bonds with
the main chain carbonyl oxygen and nitrogen atoms of residue
N260. The base is also sandwiched between the phenyl ring ofF263 and the guanidinium group of R539 (Fig. 4A and B). The a-
phosphate interacts with the R251 guanidinium group, while
R539 interacts with the c-phosphate and H259 with both the b-
and c-phosphates. Electron density for the magnesium ions that
are usually coordinated in the active site was not visible in our
structures. Absence of divalent cation has been reported for the
histidine [43], phenylalanine [44,45] and proline [46] aminoacyla-
tion systems, with replacement activation mechanisms. The diva-
lent cation activation mechanism is well documented for E. coli
KRS [18] and all residues involved are conserved in the human
and Entamoeba KRS. It is reasonable to assume that EhKRS follows
the same activation mechanism, although we cannot explain the
absence of visible cation at this point.
In the presence of both ATP and lysine in the crystallization
reaction at a 5 mM concentration, Lys-AMP was observed in the
crystal structure. This corresponds to the ﬁrst step of the aminoa-
cylation reaction, which could take place since MgCl2 was present
in the crystallization solution. In this structure the a-phosphate
adopts a different position as a consequence of bond formation
with the a-carbon of the lysine molecule (Fig. 4C). The interaction
with the adenosine moiety of Lys-AMP is similar to that observed
for ATP, but presents additional interactions: E253 interacts with
the adenine base N6 atom, and the E480 and I481 main chain car-
bonyl interact with the ribose hydroxyl groups. For the lysine moi-
ety, the a-carbonyl group interacts with R251 and the bridging
oxygen with N483. The a-amino group interacts with the E229
and E267 carboxyl groups and the G205 main chain oxygen atom.
The lysine side chain nitrogen atom interacts with the E229 and
E487 carboxyl groups and the Y269 hydroxyl group. All residues
interacting with Lys-AMP are conserved and adopt the same con-
formation as in other known complex KRS structures, like HsKRS
(Fig. 4C). Therefore, the catalytic site of EhKRS does not provide
Fig. 6. tRNA binding models of Entamoeba histolytica KRS (A) and DRS (B). For clarity only one aaRS monomer and one tRNA molecule are drawn. The aaRS are drawn as
surface models with colours from Fig. 1. The two aaRS are in the same orientation.
4484 L. Bonnefond et al. / FEBS Letters 588 (2014) 4478–4486us with any apparent opportunity for the design of a selective
inhibitor of the amino acid activation reaction.
3.4. Conformational changes upon lysine binding
In the Lys-AMP bound EhKRS structure, large conformational
changes are observed as compared to the 3 other structures that
are highly similar (with rmsd values around 0.4 Å among them,
Fig. 5A and Table 2). A large part of the catalytic domain (residues
272–490, containing the KRS-speciﬁc insertion domain) undergoes
a rigid body rotation of 13 to close the catalytic site. This move-
ment is accompanied by the ordering of a ﬁrst loop between heli-
ces a15 and a16 (residues 507–513), and the movement of a
second loop between strands b9 and b10 (residues 201–211)
toward the Lys-AMP molecule. This second loop adopts a confor-
mation that brings G205 within interaction distance from the a-
amino group of the substrate lysine. The ﬁrst loop (507–513) is
sandwiched between helix a15 and the second loop (201–211).
All these conformational changes have the effect of closing up
the active site around the bound Lys-AMP molecule. Similar con-
formational changes upon lysine binding have previously been
observed and described for E. coli (Fig. 5B) [19], T. thermophilus
KRS [20] and PfKRS [24]. However, the catalytic domain rotation
observed in the case of EhKRS is larger than in the other structures.
This may result from the absence of crystal packing interactions
involving this domain, giving it a higher degree of liberty in the
crystal as compared to the other KRS structures. Indeed a differ-
ence was also observed between E. coli LysS and LysU, the two iso-
forms of KRS in E. coli [18]. The LysS crystals were grown in the
absence of substrate and then soaked into lysine-containing solu-
tions, whereas LysU has been cocrystallized in the presence of
lysine. The insertion domain was involved in crystal contacts in
the LysS crystals, which may not be compatible with a complete
conformational change without disrupting the crystal lattice. Sim-
ilar conformational changes may occur in KRS of other organisms,
but the crystal structures of these enzymes in complex with differ-
ent ligands are missing.
3.5. Entamoeba speciﬁc helix bundle domain
Aside from the EELP at the C-terminal end of the protein, EhKRS
also contains a 58 amino acid long insertion in the catalytic domain
between strands b13 and b14 (Fig. 1). At the primary sequence
level, this insertion is only found in KRS from the Entamoeba genus.
In the EhKRS structures solved here, only partial electron density
is visible in the area that this insertion may occupy. In the EhKRS
apo-form crystal structure the electron density was slightlystronger and the domain main chain could be built for the insertion
with the help of secondary structure predictions. Due to the poor
quality of the electron density map, the residues side chains could
not be traced and only alanine residues were built. Also, the loop
connecting the different helices were often not visible and the
order of the secondary elements should thus be taken with caution
(Fig. 2B). This domain consists mainly of small a helices, one of
them (a11) with 3 lysine residues on the same side of the helix.
A structure search was performed on the domain conformation
with PDBePISA [47], but no signiﬁcant hit was found. This small
helix bundle creates a protrusion from the aaRS catalytic domain,
which may reach a bound tRNA molecule.
A model of a bound tRNA was built using the crystal structure of
DRS/tRNAAsp complex from yeast (PDBID 1ASY, [36]). Judging from
this model, the EhKRS helix bundle may indeed be able to contact
the tRNA elbow (Fig. 6A). In our superimposition, the linker con-
necting the catalytic domain to EELP clashed with the tRNA mole-
cule. In solution this helix, and therefore also EELP, should adopt an
orientation compatible with binding of the tRNA. The EhDRS also
present an Entamoeba-speciﬁc insertion sequence of 43 residues
that folds into an helix-turn-helix. A docking model with yeast
tRNAAsp shows that this extension extends at least 15 Å away from
the bulk of the aaRS and may interact with the tRNA elbow via its
lysine-rich helices (PDBID 3I7F, [37], Fig. 6B). It is interesting to
note that class IIb aaRS from human (DRS, KRS, NRS) contain a N-
terminal extension with a RNA-binding motif, which is missing
in the Entamoeba homologs. However EhNRS does not harbor any
speciﬁc insertion (PDBID 3M4Q, [48]). Still, as was already sug-
gested for the EhDRS structure [37], it is tempting to speculate that
the Entamoeba insertions compensate for the lack of the N-termi-
nal extensions in the tRNA binding. This hypothesis should be ver-
iﬁed by functional assays with cognate tRNA molecules and
recombinant EhKRS and EhDRS. Yet, this small helix bundle is an
interesting potential target for the development of new drugs tar-
geting the Entamoeba parasite.Acknowledgements
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